Market News for Boston Scientific Corp (BSX)
Boston Scientific has declined over 35% in six months, yet maintains double-digit growth and 28% operating margins, creating a compelling buy opportunity. BSX trades at mid-tier valuations, despite a 5-year revenue CAGR of 15.1% and EBITDA CAGR of 19%, outpacing Medtronic and Edwards Lifesciences. Growth drivers include electrophysiology, the WATCHMAN CHAMPION trial, and M&A, with the potential to expand the addressable market and sustain 11% EPS growth....
Seeking Alpha - 4/1/2026 4:43:53 AM
More News for BSX
Stock Analysis for BSX
Related Stocks:
